Log in using OpenID

Fibrosarcoma Drugs Market Set Explosive Growth to 2026

Fibrosarcoma is a rare type of soft tissue malignant tumour composed solely of fibre-forming connective tissue called as fibroblasts. Although, this condition can occur at any age, it is commonly diagnosed between the age of 30-60 years.
Fibrosarcoma Drugs Market Enhancement in
Medical Sector 2018 to 2026
Fibrosarcoma Drugs Market by Type (Adult Fibrosarcoma and Infantile
Fibrosarcoma) by Active Ingredient (Doxorubicin Hydrocholride, Ifosfamide,
Dacarbazine, Pazopanib Hydrochloride, and Other Active Ingredient) by Route
of Administration (Oral and Injectable) by Distribution Channel (Hospital
Pharmacies and Retail Pharmacies) - Global Industry Insights, Trends, Outlook
and Opportunity Analysis 2018- 2026
Fibrosarcoma is a rare type of soft tissue malignant tumour composed solely of fibre-forming
connective tissue called as fibroblasts. Although, this condition can occur at any age, it is commonly
diagnosed between the age of 30-60 years. Patients suffering from genetic conditions such as
retinoblastoma, nevoid basal cell carcinoma syndrome are more prone to develop fibrosarcoma.
However, precise cause of disease is unknown. Furthermore, individuals undergoing radiation therapy
or having lymphedema or get exposed to chemicals such as thorium dioxide vinyl chloride or arsenic
are more prone to fibrosarcoma. Click To Read More On Fibrosarcoma Drugs Market
This disease is symptomized by muscular pain, which increases exponentially with time. It is diagnosed
by bone lesions in radiograph, followed by advanced imaging and laboratory test and confirmed by
biopsy results. Treatment of the disease depends on the stage of tumour during diagnosis. Surgery and
radiation therapy are the treatment used for fibrosarcoma. Currently, limited number of treatment
methods and various side effects of chemotherapy such as hair loss or low blood platelet count are
propelling demand for research and development activities in fibrosarcoma treatment.
Fibrosarcoma Drugs Market Driver
Increasing research activities are expected to fuel the growth of fibrosarcoma drugs market over the
forecast period. Fibrosarcoma being malignant tumor requires early removal through complete
eradication of malignant cells by chemotherapy. Currently available chemotherapy includes side-effects
such as acquirance of multi-drug resistance (MDR), severe side-effects and high rate of reoccurrence,
which in turn demands for safer drug for chemotherapy. For instance, Loxo Oncology Inc., 2017,
received US FDA approval for investigational new drug application for LOXO 195, a next-generation
TRK inhibitor for treatment of patients with cancers that have acquired resistance to initial TRK
therapy such as larotrectinib. Moreover, in the same year, LOXO oncology announced partnership with
Bayer for the global development and commercialization of Larotrectinib and LOXO-195. The novel
drug combination studies, clinical trial for targeted drug delivery and genetic profile based medication
are expected to boost growth of the fibrosarcoma drugs market over the forecast period.
Increasing prevalence of fibrosarcoma is expected to augment growth of the fibrosarcoma drugs
market. According to American Society of Clinical Oncology, 2017, around 3260 individuals were
diagnosed by primary bone cancer in U.S. out of which 4% of adults are suffering from fibrosarcoma
and prevalence of the disease is higher in men than in women. Currently, diagnosis facility lacks in
early and accurate detection of fibrosarcoma. Therefore, rising awareness for disease and advancement
in diagnostic as well as therapeutic procedures are expected to propel growth of the fibrosarcoma drugs
market. Furthermore, companies, universities, and institutes are taking initiatives to provide
inexpensive, readily available drugs with less side-effects as compared to present drugs that will help
key players to strengthen product portfolio, in turn driving growth of the fibrosarcoma drug market.
Fibrosarcoma Drugs Market- Competitor
Major players operating in fibrosarcoma drugs market include Cadila Healthcare Limited, BristolMyers Squibb Company, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Baxter
International Inc., Eli Lilly and Company, Pfizer limited, Johnson & Johnson., and Celon Laboratories
Pvt. Ltd.
Ask For Sample Copy Of This Business Research Report :
Key players as well as government organization such as Nation Cancer Institute or American Society of
Clinical Oncology sponsors or collaborate for the development of novel therapies and drugs. For
instance, Bayer partners with loxo oncology to develop and commercialise cancer therapies.
Furthermore, Bristol-Myers Squibb Company acquired IFM therapeutics, 2017, to acquire right on
preclinical stimulator of interferon genes (STING) and NLRP3 agonist programs, which are focused on
enhancing the innate immune response for tumour.
Fibrosarcoma Drugs Market- Regional Analysis
The global fibrosarcoma market is projected to hold dominant position in North America over the
forecast period, due to increasing research activities leading to better fibrosarcoma treatment.
Furthermore, well-developed healthcare infrastructure is fuelling growth of fibrosarcoma market. Asia
Pacific is expected to be fastest growing market over the forecast period due to developing healthcare
infrastructure and rising awareness regarding conditions of fibrosarcoma.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
ravikiran303   documents Email
Health and Medicine
File Size
367 KB
Report inappropriate content